Sagar V Parikh, Jennifer L Vande Voort, Anastasia K Yocum, Eric Achtyes, Fernando S Goes, Louis Nykamp, Balwinder Singh, Daniela Lopez-Vives, Cortney E Sera, Daniel Maixner, Vijay Tarnal, Jennifer Severe, Steven Bartek, Susannah J Tye, Jose Rico, Cynthia J Stoppel, Alexis Becerra, LeAnn Smart, Christina R Miller, Mark A Frye, John F Greden, William V Bobo
OBJECTIVE: We conducted an open-label clinical trial ("Bio-K") using IV ketamine for treatment-resistant depression to identify biomarkers linked to remission. Here, we report the clinical efficacy and side effect outcomes of Bio-K. METHODS: Across 4 US sites, 75 patients ages 18-65 with treatment-refractory unipolar or bipolar depression received 3 IV ketamine infusions over an 11-day period. Key exclusion criteria were psychotic symptoms, significant substance abuse, unstable medical conditions, and any use of cannabis...
March 1, 2024: Journal of Affective Disorders